aluates Reports

$ 0.0

Global Non-oncology Biopharmaceuticals Market Insights, Forecast to 2030

Published Date: December 2024

Report Code: QYRE-Auto-4J6201

Global Non oncology Biopharmaceuticals Market Insights Forecast to 2028

BUY CHAPTERS

Global Non-oncology Biopharmaceuticals Market Insights, Forecast to 2030

Code: QYRE-Auto-4J6201

Report

December 2024

Pages:129

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

Non-oncology Biopharmaceuticals Market Size

The global Non-oncology Biopharmaceuticals market is projected to grow from US$ 329360 million in 2024 to US$ 531430 million by 2030, at a Compound Annual Growth Rate (CAGR) of 8.3% during the forecast period.

Non-oncology Biopharmaceuticals Market

Biopharmaceutical, also known as a biologic (al) medical product, biological, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semi synthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, blood, blood components, allergenic, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living cells used in cell therapy. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living cells or tissues. They (or their precursors or components) are isolated from living sources—human, animal, plant, fungal, or microbial. This report studies Non-oncology biopharmaceutical which are the drugs that are used in the treatment of various diseases rather than cancer.

Market Analysis and Insights: Global Non-oncology Biopharmaceuticals Market

The US & Canada market for Non-oncology Biopharmaceuticals is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The China market for Non-oncology Biopharmaceuticals is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The Europe market for Non-oncology Biopharmaceuticals is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The global key companies of Non-oncology Biopharmaceuticals include Roche, Sanofi, Johnson & Johnson, Pfizer, Novo Nordisk, Novartis, Merck, Teva and Eli Lilly, etc. In 2023, the global top five players had a share approximately % in terms of revenue.

Non-oncology Biopharmaceuticals is widely used in various fields, such as Immunology, Endocrinology and Others,, etc. Immunology provides greatest supports to the Non-oncology Biopharmaceuticals industry development. In 2023, global % revenue of Non-oncology Biopharmaceuticals went into Immunology filed and the proportion will reach to % in 2030.

Report Covers:

This report presents an overview of global market for Non-oncology Biopharmaceuticals market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Non-oncology Biopharmaceuticals, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Non-oncology Biopharmaceuticals, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Non-oncology Biopharmaceuticals revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Non-oncology Biopharmaceuticals market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Non-oncology Biopharmaceuticals revenue, projected growth trends, production technology, application and end-user industry.

Market Segmentation

Scope of Non-oncology Biopharmaceuticals Market Report

Report Metric	Details
Report Name	Non-oncology Biopharmaceuticals Market
Accounted market size in 2024	US$ 329360 million
Forecasted market size in 2030	US$ 531430 million
CAGR	8.3
Base Year	2024
Forecasted years	2025 - 2030
Segment by Type	Biologics Biosimilars
Segment by Application	Immunology Endocrinology Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Roche, Sanofi, Johnson & Johnson, Pfizer, Novo Nordisk, Novartis, Merck, Teva, Eli Lilly, Bristol-Myers Squibb, GlaxoSmithKline, UCB Pharma, Amgen, AbbVie, Takeda, AstraZeneca, Mylan, LEO Pharma, Boehringer Ingelheim, Alexion Pharmaceuticals, Elusys Therapeutics, Swedish Orphan Biovitrum, Biogen
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Non-oncology Biopharmaceuticals in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-oncology Biopharmaceuticals companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Non-oncology Biopharmaceuticals revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

FAQ for this report

How fast is Non-oncology Biopharmaceuticals Market growing?

Ans: The Non-oncology Biopharmaceuticals Market witnessing a CAGR of 8.3 during the forecast period 2025-2030.

What is the Non-oncology Biopharmaceuticals Market size in 2030?

Ans: The Non-oncology Biopharmaceuticals Market size in 2030 will be US$ 531430 million.

Who are the main players in the Non-oncology Biopharmaceuticals Market report?

Ans: The main players in the Non-oncology Biopharmaceuticals Market are Roche, Sanofi, Johnson & Johnson, Pfizer, Novo Nordisk, Novartis, Merck, Teva, Eli Lilly, Bristol-Myers Squibb, GlaxoSmithKline, UCB Pharma, Amgen, AbbVie, Takeda, AstraZeneca, Mylan, LEO Pharma, Boehringer Ingelheim, Alexion Pharmaceuticals, Elusys Therapeutics, Swedish Orphan Biovitrum, Biogen

What are the Application segmentation covered in the Non-oncology Biopharmaceuticals Market report?

Ans: The Applications covered in the Non-oncology Biopharmaceuticals Market report are Immunology, Endocrinology, Others

What are the Type segmentation covered in the Non-oncology Biopharmaceuticals Market report?

Ans: The Types covered in the Non-oncology Biopharmaceuticals Market report are Biologics, Biosimilars

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Type, 2019 VS 2023 VS 2030

1.2.2 Biologics

1.2.3 Biosimilars

1.3 Market by Application

1.3.1 Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Application, 2019 VS 2023 VS 2030

1.3.2 Immunology

1.3.3 Endocrinology

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Non-oncology Biopharmaceuticals Market Perspective (2019-2030)

2.2 Global Non-oncology Biopharmaceuticals Growth Trends by Region

2.2.1 Non-oncology Biopharmaceuticals Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Non-oncology Biopharmaceuticals Historic Market Size by Region (2019-2024)

2.2.3 Non-oncology Biopharmaceuticals Forecasted Market Size by Region (2025-2030)

2.3 Non-oncology Biopharmaceuticals Market Dynamics

2.3.1 Non-oncology Biopharmaceuticals Industry Trends

2.3.2 Non-oncology Biopharmaceuticals Market Drivers

2.3.3 Non-oncology Biopharmaceuticals Market Challenges

2.3.4 Non-oncology Biopharmaceuticals Market Restraints

3 Competition Landscape by Key Players

3.1 Global Revenue Non-oncology Biopharmaceuticals by Players

3.1.1 Global Non-oncology Biopharmaceuticals Revenue by Players (2019-2024)

3.1.2 Global Non-oncology Biopharmaceuticals Revenue Market Share by Players (2019-2024)

3.2 Global Non-oncology Biopharmaceuticals Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players of Non-oncology Biopharmaceuticals, Ranking by Revenue, 2022 VS 2023 VS 2024

3.4 Global Non-oncology Biopharmaceuticals Market Concentration Ratio

3.4.1 Global Non-oncology Biopharmaceuticals Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Non-oncology Biopharmaceuticals Revenue in 2023

3.5 Global Key Players of Non-oncology Biopharmaceuticals Head office and Area Served

3.6 Global Key Players of Non-oncology Biopharmaceuticals, Product and Application

3.7 Global Key Players of Non-oncology Biopharmaceuticals, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Non-oncology Biopharmaceuticals Breakdown Data by Type

4.1 Global Non-oncology Biopharmaceuticals Historic Market Size by Type (2019-2024)

4.2 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Type (2025-2030)

5 Non-oncology Biopharmaceuticals Breakdown Data by Application

5.1 Global Non-oncology Biopharmaceuticals Historic Market Size by Application (2019-2024)

5.2 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Non-oncology Biopharmaceuticals Market Size (2019-2030)

6.2 North America Non-oncology Biopharmaceuticals Market Size by Type

6.2.1 North America Non-oncology Biopharmaceuticals Market Size by Type (2019-2024)

6.2.2 North America Non-oncology Biopharmaceuticals Market Size by Type (2025-2030)

6.2.3 North America Non-oncology Biopharmaceuticals Market Share by Type (2019-2030)

6.3 North America Non-oncology Biopharmaceuticals Market Size by Application

6.3.1 North America Non-oncology Biopharmaceuticals Market Size by Application (2019-2024)

6.3.2 North America Non-oncology Biopharmaceuticals Market Size by Application (2025-2030)

6.3.3 North America Non-oncology Biopharmaceuticals Market Share by Application (2019-2030)

6.4 North America Non-oncology Biopharmaceuticals Market Size by Country

6.4.1 North America Non-oncology Biopharmaceuticals Market Size by Country: 2019 VS 2023 VS 2030

6.4.2 North America Non-oncology Biopharmaceuticals Market Size by Country (2019-2024)

6.4.3 North America Non-oncology Biopharmaceuticals Market Size by Country (2025-2030)

6.4.4 U.S.

6.4.5 Canada

7 Europe

7.1 Europe Non-oncology Biopharmaceuticals Market Size (2019-2030)

7.2 Europe Non-oncology Biopharmaceuticals Market Size by Type

7.2.1 Europe Non-oncology Biopharmaceuticals Market Size by Type (2019-2024)

7.2.2 Europe Non-oncology Biopharmaceuticals Market Size by Type (2025-2030)

7.2.3 Europe Non-oncology Biopharmaceuticals Market Share by Type (2019-2030)

7.3 Europe Non-oncology Biopharmaceuticals Market Size by Application

7.3.1 Europe Non-oncology Biopharmaceuticals Market Size by Application (2019-2024)

7.3.2 Europe Non-oncology Biopharmaceuticals Market Size by Application (2025-2030)

7.3.3 Europe Non-oncology Biopharmaceuticals Market Share by Application (2019-2030)

7.4 Europe Non-oncology Biopharmaceuticals Market Size by Country

7.4.1 Europe Non-oncology Biopharmaceuticals Market Size by Country: 2019 VS 2023 VS 2030

7.4.2 Europe Non-oncology Biopharmaceuticals Market Size by Country (2019-2024)

7.4.3 Europe Non-oncology Biopharmaceuticals Market Size by Country (2025-2030)

7.4.3 Germany

7.4.4 France

7.4.5 U.K.

7.4.6 Italy

7.4.7 Russia

7.4.8 Nordic Countries

8 China

8.1 China Non-oncology Biopharmaceuticals Market Size (2019-2030)

8.2 China Non-oncology Biopharmaceuticals Market Size by Type

8.2.1 China Non-oncology Biopharmaceuticals Market Size by Type (2019-2024)

8.2.2 China Non-oncology Biopharmaceuticals Market Size by Type (2025-2030)

8.2.3 China Non-oncology Biopharmaceuticals Market Share by Type (2019-2030)

8.3 China Non-oncology Biopharmaceuticals Market Size by Application

8.3.1 China Non-oncology Biopharmaceuticals Market Size by Application (2019-2024)

8.3.2 China Non-oncology Biopharmaceuticals Market Size by Application (2025-2030)

8.3.3 China Non-oncology Biopharmaceuticals Market Share by Application (2019-2030)

9 Asia (excluding China)

9.1 Asia Non-oncology Biopharmaceuticals Market Size (2019-2030)

9.2 Asia Non-oncology Biopharmaceuticals Market Size by Type

9.2.1 Asia Non-oncology Biopharmaceuticals Market Size by Type (2019-2024)

9.2.2 Asia Non-oncology Biopharmaceuticals Market Size by Type (2025-2030)

9.2.3 Asia Non-oncology Biopharmaceuticals Market Share by Type (2019-2030)

9.3 Asia Non-oncology Biopharmaceuticals Market Size by Application

9.3.1 Asia Non-oncology Biopharmaceuticals Market Size by Application (2019-2024)

9.3.2 Asia Non-oncology Biopharmaceuticals Market Size by Application (2025-2030)

9.3.3 Asia Non-oncology Biopharmaceuticals Market Share by Application (2019-2030)

9.4 Asia Non-oncology Biopharmaceuticals Market Size by Region

9.4.1 Asia Non-oncology Biopharmaceuticals Market Size by Region: 2019 VS 2023 VS 2030

9.4.2 Asia Non-oncology Biopharmaceuticals Market Size by Region (2019-2024)

9.4.3 Asia Non-oncology Biopharmaceuticals Market Size by Region (2025-2030)

9.4.4 Japan

9.4.5 South Korea

9.4.6 China Taiwan

9.4.7 Southeast Asia

9.4.8 India

9.4.9 Australia

10 Middle East, Africa, and Latin America

10.1 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size (2019-2030)

10.2 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Type

10.2.1 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Type (2019-2024)

10.2.2 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Type (2025-2030)

10.2.3 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Share by Type (2019-2030)

10.3 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Application

10.3.1 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Application (2019-2024)

10.3.2 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Application (2025-2030)

10.3.3 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Share by Application (2019-2030)

10.4 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Country

10.4.1 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Country: 2019 VS 2023 VS 2030

10.4.2 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Country (2019-2024)

10.4.3 Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Country (2025-2030)

10.4.4 Brazil

10.4.5 Mexico

10.4.6 Turkey

10.4.7 Saudi Arabia

10.4.8 Israel

10.4.9 GCC Countries

11 Key Players Profiles

11.1 Roche

11.1.1 Roche Company Details

11.1.2 Roche Business Overview

11.1.3 Roche Non-oncology Biopharmaceuticals Introduction

11.1.4 Roche Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.1.5 Roche Recent Developments

11.2 Sanofi

11.2.1 Sanofi Company Details

11.2.2 Sanofi Business Overview

11.2.3 Sanofi Non-oncology Biopharmaceuticals Introduction

11.2.4 Sanofi Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.2.5 Sanofi Recent Developments

11.3 Johnson & Johnson

11.3.1 Johnson & Johnson Company Details

11.3.2 Johnson & Johnson Business Overview

11.3.3 Johnson & Johnson Non-oncology Biopharmaceuticals Introduction

11.3.4 Johnson & Johnson Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.3.5 Johnson & Johnson Recent Developments

11.4 Pfizer

11.4.1 Pfizer Company Details

11.4.2 Pfizer Business Overview

11.4.3 Pfizer Non-oncology Biopharmaceuticals Introduction

11.4.4 Pfizer Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.4.5 Pfizer Recent Developments

11.5 Novo Nordisk

11.5.1 Novo Nordisk Company Details

11.5.2 Novo Nordisk Business Overview

11.5.3 Novo Nordisk Non-oncology Biopharmaceuticals Introduction

11.5.4 Novo Nordisk Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.5.5 Novo Nordisk Recent Developments

11.6 Novartis

11.6.1 Novartis Company Details

11.6.2 Novartis Business Overview

11.6.3 Novartis Non-oncology Biopharmaceuticals Introduction

11.6.4 Novartis Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.6.5 Novartis Recent Developments

11.7 Merck

11.7.1 Merck Company Details

11.7.2 Merck Business Overview

11.7.3 Merck Non-oncology Biopharmaceuticals Introduction

11.7.4 Merck Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.7.5 Merck Recent Developments

11.8 Teva

11.8.1 Teva Company Details

11.8.2 Teva Business Overview

11.8.3 Teva Non-oncology Biopharmaceuticals Introduction

11.8.4 Teva Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.8.5 Teva Recent Developments

11.9 Eli Lilly

11.9.1 Eli Lilly Company Details

11.9.2 Eli Lilly Business Overview

11.9.3 Eli Lilly Non-oncology Biopharmaceuticals Introduction

11.9.4 Eli Lilly Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.9.5 Eli Lilly Recent Developments

11.10 Bristol-Myers Squibb

11.10.1 Bristol-Myers Squibb Company Details

11.10.2 Bristol-Myers Squibb Business Overview

11.10.3 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Introduction

11.10.4 Bristol-Myers Squibb Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.10.5 Bristol-Myers Squibb Recent Developments

11.11 GlaxoSmithKline

11.11.1 GlaxoSmithKline Company Details

11.11.2 GlaxoSmithKline Business Overview

11.11.3 GlaxoSmithKline Non-oncology Biopharmaceuticals Introduction

11.11.4 GlaxoSmithKline Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.11.5 GlaxoSmithKline Recent Developments

11.12 UCB Pharma

11.12.1 UCB Pharma Company Details

11.12.2 UCB Pharma Business Overview

11.12.3 UCB Pharma Non-oncology Biopharmaceuticals Introduction

11.12.4 UCB Pharma Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.12.5 UCB Pharma Recent Developments

11.13 Amgen

11.13.1 Amgen Company Details

11.13.2 Amgen Business Overview

11.13.3 Amgen Non-oncology Biopharmaceuticals Introduction

11.13.4 Amgen Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.13.5 Amgen Recent Developments

11.14 AbbVie

11.14.1 AbbVie Company Details

11.14.2 AbbVie Business Overview

11.14.3 AbbVie Non-oncology Biopharmaceuticals Introduction

11.14.4 AbbVie Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.14.5 AbbVie Recent Developments

11.15 Takeda

11.15.1 Takeda Company Details

11.15.2 Takeda Business Overview

11.15.3 Takeda Non-oncology Biopharmaceuticals Introduction

11.15.4 Takeda Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.15.5 Takeda Recent Developments

11.16 AstraZeneca

11.16.1 AstraZeneca Company Details

11.16.2 AstraZeneca Business Overview

11.16.3 AstraZeneca Non-oncology Biopharmaceuticals Introduction

11.16.4 AstraZeneca Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.16.5 AstraZeneca Recent Developments

11.17 Mylan

11.17.1 Mylan Company Details

11.17.2 Mylan Business Overview

11.17.3 Mylan Non-oncology Biopharmaceuticals Introduction

11.17.4 Mylan Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.17.5 Mylan Recent Developments

11.18 LEO Pharma

11.18.1 LEO Pharma Company Details

11.18.2 LEO Pharma Business Overview

11.18.3 LEO Pharma Non-oncology Biopharmaceuticals Introduction

11.18.4 LEO Pharma Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.18.5 LEO Pharma Recent Developments

11.19 Boehringer Ingelheim

11.19.1 Boehringer Ingelheim Company Details

11.19.2 Boehringer Ingelheim Business Overview

11.19.3 Boehringer Ingelheim Non-oncology Biopharmaceuticals Introduction

11.19.4 Boehringer Ingelheim Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.19.5 Boehringer Ingelheim Recent Developments

11.20 Alexion Pharmaceuticals

11.20.1 Alexion Pharmaceuticals Company Details

11.20.2 Alexion Pharmaceuticals Business Overview

11.20.3 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Introduction

11.20.4 Alexion Pharmaceuticals Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.20.5 Alexion Pharmaceuticals Recent Developments

11.21 Elusys Therapeutics

11.21.1 Elusys Therapeutics Company Details

11.21.2 Elusys Therapeutics Business Overview

11.21.3 Elusys Therapeutics Non-oncology Biopharmaceuticals Introduction

11.21.4 Elusys Therapeutics Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.21.5 Elusys Therapeutics Recent Developments

11.22 Swedish Orphan Biovitrum

11.22.1 Swedish Orphan Biovitrum Company Details

11.22.2 Swedish Orphan Biovitrum Business Overview

11.22.3 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Introduction

11.22.4 Swedish Orphan Biovitrum Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.22.5 Swedish Orphan Biovitrum Recent Developments

11.23 Biogen

11.23.1 Biogen Company Details

11.23.2 Biogen Business Overview

11.23.3 Biogen Non-oncology Biopharmaceuticals Introduction

11.23.4 Biogen Revenue in Non-oncology Biopharmaceuticals Business (2019-2024)

11.23.5 Biogen Recent Developments

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

Table 1. Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030

Table 2. Key Players of Biologics

Table 3. Key Players of Biosimilars

Table 4. Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030

Table 5. Global Non-oncology Biopharmaceuticals Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global Non-oncology Biopharmaceuticals Market Size by Region (2019-2024) & (US$ Million)

Table 7. Global Non-oncology Biopharmaceuticals Market Share by Region (2019-2024)

Table 8. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 9. Global Non-oncology Biopharmaceuticals Market Share by Region (2025-2030)

Table 10. Non-oncology Biopharmaceuticals Market Trends

Table 11. Non-oncology Biopharmaceuticals Market Drivers

Table 12. Non-oncology Biopharmaceuticals Market Challenges

Table 13. Non-oncology Biopharmaceuticals Market Restraints

Table 14. Global Non-oncology Biopharmaceuticals Revenue by Players (2019-2024) & (US$ Million)

Table 15. Global Non-oncology Biopharmaceuticals Revenue Share by Players (2019-2024)

Table 16. Global Top Non-oncology Biopharmaceuticals by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-oncology Biopharmaceuticals as of 2023)

Table 17. Global Non-oncology Biopharmaceuticals Industry Ranking 2022 VS 2023 VS 2024

Table 18. Global 5 Largest Players Market Share by Non-oncology Biopharmaceuticals Revenue (CR5 and HHI) & (2019-2024)

Table 19. Global Key Players of Non-oncology Biopharmaceuticals, Headquarters and Area Served

Table 20. Global Key Players of Non-oncology Biopharmaceuticals, Product and Application

Table 21. Global Key Players of Non-oncology Biopharmaceuticals, Product and Application

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Non-oncology Biopharmaceuticals Market Size by Type (2019-2024) & (US$ Million)

Table 24. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2019-2024)

Table 25. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 26. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2025-2030)

Table 27. Global Non-oncology Biopharmaceuticals Market Size by Application (2019-2024) & (US$ Million)

Table 28. Global Non-oncology Biopharmaceuticals Revenue Share by Application (2019-2024)

Table 29. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 30. Global Non-oncology Biopharmaceuticals Revenue Share by Application (2025-2030)

Table 31. North America Non-oncology Biopharmaceuticals Market Size by Type (2019-2024) & (US$ Million)

Table 32. North America Non-oncology Biopharmaceuticals Market Size by Type (2025-2030) & (US$ Million)

Table 33. North America Non-oncology Biopharmaceuticals Market Size by Application (2019-2024) & (US$ Million)

Table 34. North America Non-oncology Biopharmaceuticals Market Size by Application (2025-2030) & (US$ Million)

Table 35. North America Non-oncology Biopharmaceuticals Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 36. North America Non-oncology Biopharmaceuticals Market Size by Country (2019-2024) & (US$ Million)

Table 37. North America Non-oncology Biopharmaceuticals Market Size by Country (2025-2030) & (US$ Million)

Table 38. Europe Non-oncology Biopharmaceuticals Market Size by Type (2019-2024) & (US$ Million)

Table 39. Europe Non-oncology Biopharmaceuticals Market Size by Type (2025-2030) & (US$ Million)

Table 40. Europe Non-oncology Biopharmaceuticals Market Size by Application (2019-2024) & (US$ Million)

Table 41. Europe Non-oncology Biopharmaceuticals Market Size by Application (2025-2030) & (US$ Million)

Table 42. Europe Non-oncology Biopharmaceuticals Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 43. Europe Non-oncology Biopharmaceuticals Market Size by Country (2019-2024) & (US$ Million)

Table 44. Europe Non-oncology Biopharmaceuticals Market Size by Country (2025-2030) & (US$ Million)

Table 45. China Non-oncology Biopharmaceuticals Market Size by Type (2019-2024) & (US$ Million)

Table 46. China Non-oncology Biopharmaceuticals Market Size by Type (2025-2030) & (US$ Million)

Table 47. China Non-oncology Biopharmaceuticals Market Size by Application (2019-2024) & (US$ Million)

Table 48. China Non-oncology Biopharmaceuticals Market Size by Application (2025-2030) & (US$ Million)

Table 49. Asia Non-oncology Biopharmaceuticals Market Size by Type (2019-2024) & (US$ Million)

Table 50. Asia Non-oncology Biopharmaceuticals Market Size by Type (2025-2030) & (US$ Million)

Table 51. Asia Non-oncology Biopharmaceuticals Market Size by Application (2019-2024) & (US$ Million)

Table 52. Asia Non-oncology Biopharmaceuticals Market Size by Application (2025-2030) & (US$ Million)

Table 53. Asia Non-oncology Biopharmaceuticals Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030

Table 54. Asia Non-oncology Biopharmaceuticals Market Size by Region (2019-2024) & (US$ Million)

Table 55. Asia Non-oncology Biopharmaceuticals Market Size by Region (2025-2030) & (US$ Million)

Table 56. Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Type (2019-2024) & (US$ Million)

Table 57. Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Type (2025-2030) & (US$ Million)

Table 58. Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Application (2019-2024) & (US$ Million)

Table 59. Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Application (2025-2030) & (US$ Million)

Table 60. Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 61. Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Country (2019-2024) & (US$ Million)

Table 62. Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size by Country (2025-2030) & (US$ Million)

Table 63. Roche Company Details

Table 64. Roche Business Overview

Table 65. Roche Non-oncology Biopharmaceuticals Product

Table 66. Roche Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 67. Roche Recent Developments

Table 68. Sanofi Company Details

Table 69. Sanofi Business Overview

Table 70. Sanofi Non-oncology Biopharmaceuticals Product

Table 71. Sanofi Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 72. Sanofi Recent Developments

Table 73. Johnson & Johnson Company Details

Table 74. Johnson & Johnson Business Overview

Table 75. Johnson & Johnson Non-oncology Biopharmaceuticals Product

Table 76. Johnson & Johnson Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 77. Johnson & Johnson Recent Developments

Table 78. Pfizer Company Details

Table 79. Pfizer Business Overview

Table 80. Pfizer Non-oncology Biopharmaceuticals Product

Table 81. Pfizer Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 82. Pfizer Recent Developments

Table 83. Novo Nordisk Company Details

Table 84. Novo Nordisk Business Overview

Table 85. Novo Nordisk Non-oncology Biopharmaceuticals Product

Table 86. Novo Nordisk Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 87. Novo Nordisk Recent Developments

Table 88. Novartis Company Details

Table 89. Novartis Business Overview

Table 90. Novartis Non-oncology Biopharmaceuticals Product

Table 91. Novartis Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 92. Novartis Recent Developments

Table 93. Merck Company Details

Table 94. Merck Business Overview

Table 95. Merck Non-oncology Biopharmaceuticals Product

Table 96. Merck Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 97. Merck Recent Developments

Table 98. Teva Company Details

Table 99. Teva Business Overview

Table 100. Teva Non-oncology Biopharmaceuticals Product

Table 101. Teva Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 102. Teva Recent Developments

Table 103. Eli Lilly Company Details

Table 104. Eli Lilly Business Overview

Table 105. Eli Lilly Non-oncology Biopharmaceuticals Product

Table 106. Eli Lilly Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 107. Eli Lilly Recent Developments

Table 108. Bristol-Myers Squibb Company Details

Table 109. Bristol-Myers Squibb Business Overview

Table 110. Bristol-Myers Squibb Non-oncology Biopharmaceuticals Product

Table 111. Bristol-Myers Squibb Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 112. Bristol-Myers Squibb Recent Developments

Table 113. GlaxoSmithKline Company Details

Table 114. GlaxoSmithKline Business Overview

Table 115. GlaxoSmithKline Non-oncology Biopharmaceuticals Product

Table 116. GlaxoSmithKline Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 117. GlaxoSmithKline Recent Developments

Table 118. UCB Pharma Company Details

Table 119. UCB Pharma Business Overview

Table 120. UCB Pharma Non-oncology Biopharmaceuticals Product

Table 121. UCB Pharma Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 122. UCB Pharma Recent Developments

Table 123. Amgen Company Details

Table 124. Amgen Business Overview

Table 125. Amgen Non-oncology Biopharmaceuticals Product

Table 126. Amgen Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 127. Amgen Recent Developments

Table 128. AbbVie Company Details

Table 129. AbbVie Business Overview

Table 130. AbbVie Non-oncology Biopharmaceuticals Product

Table 131. AbbVie Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 132. AbbVie Recent Developments

Table 133. Takeda Company Details

Table 134. Takeda Business Overview

Table 135. Takeda Non-oncology Biopharmaceuticals Product

Table 136. Takeda Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 137. Takeda Recent Developments

Table 138. AstraZeneca Company Details

Table 139. AstraZeneca Business Overview

Table 140. AstraZeneca Non-oncology Biopharmaceuticals Product

Table 141. AstraZeneca Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 142. AstraZeneca Recent Developments

Table 143. Mylan Company Details

Table 144. Mylan Business Overview

Table 145. Mylan Non-oncology Biopharmaceuticals Product

Table 146. Mylan Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 147. Mylan Recent Developments

Table 148. LEO Pharma Company Details

Table 149. LEO Pharma Business Overview

Table 150. LEO Pharma Non-oncology Biopharmaceuticals Product

Table 151. LEO Pharma Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 152. LEO Pharma Recent Developments

Table 153. Boehringer Ingelheim Company Details

Table 154. Boehringer Ingelheim Business Overview

Table 155. Boehringer Ingelheim Non-oncology Biopharmaceuticals Product

Table 156. Boehringer Ingelheim Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 157. Boehringer Ingelheim Recent Developments

Table 158. Alexion Pharmaceuticals Company Details

Table 159. Alexion Pharmaceuticals Business Overview

Table 160. Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Product

Table 161. Alexion Pharmaceuticals Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 162. Alexion Pharmaceuticals Recent Developments

Table 163. Elusys Therapeutics Company Details

Table 164. Elusys Therapeutics Business Overview

Table 165. Elusys Therapeutics Non-oncology Biopharmaceuticals Product

Table 166. Elusys Therapeutics Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 167. Elusys Therapeutics Recent Developments

Table 168. Swedish Orphan Biovitrum Company Details

Table 169. Swedish Orphan Biovitrum Business Overview

Table 170. Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Product

Table 171. Swedish Orphan Biovitrum Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 172. Swedish Orphan Biovitrum Recent Developments

Table 173. Biogen Company Details

Table 174. Biogen Business Overview

Table 175. Biogen Non-oncology Biopharmaceuticals Product

Table 176. Biogen Revenue in Non-oncology Biopharmaceuticals Business (2019-2024) & (US$ Million)

Table 177. Biogen Recent Developments

Table 178. Research Programs/Design for This Report

Table 179. Key Data Information from Secondary Sources

Table 180. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)

Figure 2. Global Non-oncology Biopharmaceuticals Market Share by Type: 2023 VS 2030

Figure 3. Biologics Features

Figure 4. Biosimilars Features

Figure 5. Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)

Figure 6. Global Non-oncology Biopharmaceuticals Market Share by Application: 2023 VS 2030

Figure 7. Immunology Case Studies

Figure 8. Endocrinology Case Studies

Figure 9. Others Case Studies

Figure 10. Non-oncology Biopharmaceuticals Report Years Considered

Figure 11. Global Non-oncology Biopharmaceuticals Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 12. Global Non-oncology Biopharmaceuticals Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 13. Global Non-oncology Biopharmaceuticals Market Share by Region: 2023 VS 2030

Figure 14. Global Non-oncology Biopharmaceuticals Market Share by Players in 2023

Figure 15. Global Top Non-oncology Biopharmaceuticals Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-oncology Biopharmaceuticals as of 2023)

Figure 16. The Top 10 and 5 Players Market Share by Non-oncology Biopharmaceuticals Revenue in 2023

Figure 17. North America Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 18. North America Non-oncology Biopharmaceuticals Market Share by Type (2019-2030)

Figure 19. North America Non-oncology Biopharmaceuticals Market Share by Application (2019-2030)

Figure 20. North America Non-oncology Biopharmaceuticals Market Share by Country (2019-2030)

Figure 21. United States Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. Canada Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. Europe Non-oncology Biopharmaceuticals Market Size YoY (2019-2030) & (US$ Million)

Figure 24. Europe Non-oncology Biopharmaceuticals Market Share by Type (2019-2030)

Figure 25. Europe Non-oncology Biopharmaceuticals Market Share by Application (2019-2030)

Figure 26. Europe Non-oncology Biopharmaceuticals Market Share by Country (2019-2030)

Figure 27. Germany Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. France Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. U.K. Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Italy Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Russia Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Nordic Countries Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. China Non-oncology Biopharmaceuticals Market Size YoY (2019-2030) & (US$ Million)

Figure 34. China Non-oncology Biopharmaceuticals Market Share by Type (2019-2030)

Figure 35. China Non-oncology Biopharmaceuticals Market Share by Application (2019-2030)

Figure 36. Asia Non-oncology Biopharmaceuticals Market Size YoY (2019-2030) & (US$ Million)

Figure 37. Asia Non-oncology Biopharmaceuticals Market Share by Type (2019-2030)

Figure 38. Asia Non-oncology Biopharmaceuticals Market Share by Application (2019-2030)

Figure 39. Asia Non-oncology Biopharmaceuticals Market Share by Region (2019-2030)

Figure 40. Japan Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. South Korea Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. China Taiwan Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Southeast Asia Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. India Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Australia Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Size YoY (2019-2030) & (US$ Million)

Figure 47. Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Share by Type (2019-2030)

Figure 48. Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Share by Application (2019-2030)

Figure 49. Middle East, Africa, and Latin America Non-oncology Biopharmaceuticals Market Share by Country (2019-2030)

Figure 50. Brazil Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 51. Mexico Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 52. Turkey Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 53. Saudi Arabia Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 54. Israel Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 55. GCC Countries Non-oncology Biopharmaceuticals Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 56. Roche Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 57. Sanofi Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 58. Johnson & Johnson Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 59. Pfizer Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 60. Novo Nordisk Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 61. Novartis Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 62. Merck Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 63. Teva Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 64. Eli Lilly Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 65. Bristol-Myers Squibb Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 66. GlaxoSmithKline Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 67. UCB Pharma Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 68. Amgen Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 69. AbbVie Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 70. Takeda Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 71. AstraZeneca Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 72. Mylan Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 73. LEO Pharma Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 74. Boehringer Ingelheim Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 75. Alexion Pharmaceuticals Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 76. Elusys Therapeutics Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 77. Swedish Orphan Biovitrum Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 78. Biogen Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2019-2024)

Figure 79. Bottom-up and Top-down Approaches for This Report

Figure 80. Data Triangulation

Figure 81. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Pharmaceutical Labelling Machine Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-13D10320

Thu Feb 20 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Pharmaceutical Strip Packaging Machines Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-36X10626

Thu Feb 20 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Joint Reinforcement Paste Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-29I10537

Thu Feb 20 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Pharmaceutical Coating Devcie Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-7E13021

Thu Feb 20 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global Non-oncology Biopharmaceuticals Market Insights, Forecast to 2030

Published Date: December 2024

Report Code: QYRE-Auto-4J6201

Global Non-oncology Biopharmaceuticals Market Insights, Forecast to 2030

FEATURED COMPANIES

Non-oncology Biopharmaceuticals Market Size

Non-oncology Biopharmaceuticals Market

Scope of Non-oncology Biopharmaceuticals Market Report

Chapter Outline

FAQ for this report

How fast is Non-oncology Biopharmaceuticals Market growing?

What is the Non-oncology Biopharmaceuticals Market size in 2030?

Who are the main players in the Non-oncology Biopharmaceuticals Market report?

What are the Application segmentation covered in the Non-oncology Biopharmaceuticals Market report?

What are the Type segmentation covered in the Non-oncology Biopharmaceuticals Market report?

FEATURED COMPANIES

RELATED REPORTS

$5800

Enterprise User

$5800

Enterprise User

$5800

Enterprise User

$5800

Enterprise User